In the last trading session, 1.15 million Cidara Therapeutics Inc (NASDAQ:CDTX) shares changed hands as the company’s beta touched 1.10. With the company’s per share price at $48.71 changed hands at -$0.74 or -1.50% during last session, the market valuation stood at $1.08B. CDTX’s last price was a discount, traded about -16.67% off its 52-week high of $56.83. The share price had its 52-week low at $10.14, which suggests the last value was 79.18% up since then. When we look at Cidara Therapeutics Inc’s average trading volume, we note the 10-day average is 2.16 million shares, with the 3-month average coming to 469.75K.
Analysts gave the Cidara Therapeutics Inc (CDTX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CDTX as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight.
Cidara Therapeutics Inc (NASDAQ:CDTX) trade information
Instantly CDTX was in red as seen at the end of in last trading. With action 8.36%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 334.91%, with the 5-day performance at 8.36% in the green. However, in the 30-day time frame, Cidara Therapeutics Inc (NASDAQ:CDTX) is 121.21% up. Looking at the short shares, we see there were 0.65 million shares sold at short interest cover period of 3.1 days.
The consensus price target for the stock as assigned by Wall Street analysts is 57, meaning bulls need an upside of 14.54% from its current market value. According to analyst projections, CDTX’s forecast low is 46 with 68 as the target high. To hit the forecast high, the stock’s price needs a -39.6% plunge from its current level, while the stock would need to tank 5.56% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 1.30%. The 2025 estimates are for Cidara Therapeutics Inc earnings to increase by 71.38%, but the outlook for the next 5-year period is at 36.33% per year.
CDTX Dividends
Cidara Therapeutics Inc is expected to release its next quarterly earnings report on 2025-May-08.
Cidara Therapeutics Inc (NASDAQ:CDTX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.12% of Cidara Therapeutics Inc shares while 55.45% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 56.07%. There are 55.45% institutions holding the Cidara Therapeutics Inc stock share, with MONASHEE INVESTMENT MANAGEMENT LLC the top institutional holder. As of 2024-06-30, the company held 8.0876% of the shares, roughly 0.37 million CDTX shares worth $4.41 million.
BVF INC/IL holds the second largest percentage of outstanding shares, with 7.5169% or 0.34 million shares worth $4.1 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . With 417.12 shares estimated at $20.32 million under it, the former controlled 1.95% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund held about 0.39% of the shares, roughly 82.47 shares worth around $4.02 million.
